コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rompted us to devise an expeditious route to lysergic acid.
2 thwarted the completion of the synthesis of lysergic acid.
5 etanserin (100 nM), mesulergine (100 nM) and lysergic acid diethylamide (1 microM) significantly redu
7 inding affinities were determined using [3H]-lysergic acid diethylamide ([3H]-LSD) binding to cell me
8 thylenedioxymethamphetamine (known as MDMA), lysergic acid diethylamide (known as LSD), psilocybin, o
9 Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n
11 ly receptors represent essential targets for lysergic acid diethylamide (LSD) and all other psychedel
14 uestions were asked about: use of ayahuasca, lysergic acid diethylamide (LSD) and magic mushrooms; de
15 d classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD) and N,N-dimethyltryptam
19 ound that neural and experiential effects of lysergic acid diethylamide (LSD) are attributable to ago
20 silocybin, N,N'-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renais
21 ng method for quantitation of (3)H-labeled d-lysergic acid diethylamide (LSD) binding to recombinant
22 l studies have reported that the psychedelic lysergic acid diethylamide (LSD) enhances empathy and so
24 sic psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have recaptured the ima
25 40 years, there is renewed interest in using lysergic acid diethylamide (LSD) in clinical psychiatric
29 ies have started to elucidate the effects of lysergic acid diethylamide (LSD) on the human brain but
30 -)-2,5-dimethoxy-4-iodoamphetamine (DOI) and lysergic acid diethylamide (LSD) stimulated a head-twitc
31 ere, we investigate the neural mechanisms of lysergic acid diethylamide (LSD) using regression dynami
32 nthesis of (+)-JRT, a structural analogue of lysergic acid diethylamide (LSD) with lower hallucinogen
33 linical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymeth
36 d CTSC regions after acute administration of lysergic acid diethylamide (LSD), and after pretreatment
37 Classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrypta
40 However, other 5-HT2A receptor ligands like lysergic acid diethylamide (LSD), in which the amine nit
41 ggest that repeated use of very low doses of lysergic acid diethylamide (LSD), known as microdosing,
42 nogens, including mescaline, psilocybin, and lysergic acid diethylamide (LSD), profoundly affect perc
45 ring drugs: propofol, sevoflurane, ketamine, lysergic acid diethylamide (LSD), psilocybin, N,N-Dimeth
46 elated networks underlie the peak effects of lysergic acid diethylamide (LSD), we applied dynamic cau
47 onergic psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), which have a key locus
48 ed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in pat
53 ne (selective for the 5-HT2C receptor) and d-lysergic acid diethylamide (selective for the 5-HT2A rec
54 tetrahydrocannabinol, and psychedelics like lysergic acid diethylamide all directly bind to GPCRs to
60 ed the PLC-IP pathway, whereas others (e.g., lysergic acid diethylamide) favored the PLA2-AA pathway.
61 ted by 33% of the sample, most commonly LSD (lysergic acid diethylamide), amphetamines, Ecstasy (meth
62 emical studies showing that the hallucinogen lysergic acid diethylamide, its precursor ergotamine (ER
64 hallucinogenic drugs, such as psilocybin and lysergic acid diethylamide, require the 2AR and resemble
65 viewed journals, reporting on "psilocybin," "lysergic acid diethylamide," "LSD," "ayahuasca," "3,4-me
68 ds of recent other drug use (eg, cocaine and lysergic acid diethylamide; odds ratio [OR], 1.73; 95% C
69 HT(2A) receptor, a primary site of action of lysergic acid diethylamine (LSD), appears to dominate ef
70 ential validation of this model by utilizing lysergic acid dimethylamide (DAM-57), an ergot derivativ
72 f the main ergoline therapeutic precursor, D-lysergic acid, to a titre of 1.7 mg L(-1) in a 1 L biore